MCID: PRN009
MIFTS: 49

Paranoid Schizophrenia

Categories: Mental diseases

Aliases & Classifications for Paranoid Schizophrenia

MalaCards integrated aliases for Paranoid Schizophrenia:

Name: Paranoid Schizophrenia 12 54 15 71 32
Chronic Paranoid Schizophrenia 12 71
Paranoid Type Schizophrenia Subchronic State 12
Paranoid Type Schizophrenia 12
Paraphrenic Schizophrenia 12
Schizophrenia, Paranoid 43
Paraphrenia - Late 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1229
MeSH 43 D012563
NCIt 49 C35006
SNOMED-CT 67 31658008 64905009
ICD10 32 F20.0
UMLS 71 C0036349 C0270398

Summaries for Paranoid Schizophrenia

Disease Ontology : 12 A schizophrenia characterized by delusions or auditory hallucinations of persecution or being plotted against without thought disorder, disorganized behavior, or affective flattening.

MalaCards based summary : Paranoid Schizophrenia, also known as chronic paranoid schizophrenia, is related to head injury and schizophrenia 5. An important gene associated with Paranoid Schizophrenia is COMT (Catechol-O-Methyltransferase), and among its related pathways/superpathways are Neuroscience and Serotonergic synapse. The drugs Cycloserine and Ziprasidone have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotypes are behavior/neurological and endocrine/exocrine gland

Wikipedia : 74 Paranoid schizophrenia was long diagnosed as the most common type of schizophrenia, but this sub-type is... more...

Related Diseases for Paranoid Schizophrenia

Diseases related to Paranoid Schizophrenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 215)
# Related Disease Score Top Affiliating Genes
1 head injury 30.6 S100B PRL
2 schizophrenia 5 30.5 PRL HTR2A HTR1A COMT
3 tardive dyskinesia 30.4 HTR2A COMT
4 delusional disorder 30.3 HTR2A HTR1A DRD5 DISC1
5 traumatic brain injury 30.2 S100B IL6 COMT BDNF
6 brain injury 30.2 S100B IL6 COMT BDNF
7 body dysmorphic disorder 30.2 SLC6A4 MAOA HTR2A
8 alexithymia 29.9 SLC6A4 IL6 HTR1A COMT
9 depression 29.9 TPH2 SLC6A4 MAOA HTR2A HTR1A BDNF
10 speech and communication disorders 29.8 NRXN1 IL6 COMT BDNF
11 neurotic disorder 29.7 SLC6A4 MAOA IL6 HTR2A HTR1A BDNF
12 dementia 29.6 TNF MAOA HTR2A HTR1A COMT BDNF
13 alcohol use disorder 29.6 SLC6A4 HTR2A HTR1A COMT BDNF
14 vascular dementia 29.5 TNF IL6 HTR1A
15 personality disorder 29.4 TPH2 SLC6A4 PRL MAOA HTR2A HTR1A
16 narcolepsy 29.4 TNF SLC6A4 MAOA IL6 HTR2A COMT
17 post-traumatic stress disorder 29.4 SLC6A4 MAOA HTR2A COMT CNR1 BDNF
18 endogenous depression 29.2 SLC6A4 MAOA IL6 HTR2A HTR1A COMT
19 mood disorder 28.8 TPH2 SLC6A4 MAOA IL6 HTR2A HTR1A
20 alcohol dependence 28.6 TPH2 SLC6A4 PRL MAOA HTR2A HTR1A
21 anxiety 28.4 TPH2 TNF SLC6A4 PRL NTRK2 MAOA
22 mental depression 28.4 TPH2 SLC6A4 NTRK2 MAOA IL6 HTR2A
23 obsessive-compulsive disorder 28.2 TPH2 TNF SLC6A4 PRL NTRK2 MAOA
24 schizoaffective disorder 28.1 SLC6A4 PRL NRXN1 HTR2A HTR1A DISC1
25 substance abuse 28.1 SLC6A4 PRL MIAT MAOA HTR2A HTR1A
26 autism spectrum disorder 27.4 TPH2 TNF SLC6A4 NRXN1 MAOA HTR2A
27 major depressive disorder 27.4 TPH2 TNF SLC6A4 PRL NTRK2 MAOA
28 schizophrenia 27.3 TPH2 TNF SLC6A4 S100B PRL NTRK2
29 psychotic disorder 27.2 TPH2 SLC6A4 S100B PRL NRXN1 MAOA
30 autism 26.8 TPH2 TNF SLC6A4 PRL NTRK2 NRXN1
31 bipolar disorder 26.4 TPH2 TNF SLC6A4 S100B PRL NTRK2
32 external pathological resorption 10.5 TNF IL6
33 scorpion envenomation 10.5 TNF IL6
34 idiopathic anterior uveitis 10.5 TNF IL6
35 streptococcal toxic-shock syndrome 10.5 TNF IL6
36 angioimmunoblastic lymphadenopathy with dysproteinemia 10.5 TNF IL6
37 null-cell leukemia 10.4 TNF IL6
38 non-alcoholic steatohepatitis 10.4 TNF IL6
39 mammographic density 10.4 PRL COMT
40 spinal cord injury 10.3 TNF IL6 BDNF
41 sebaceous gland disease 10.3 TNF PRL IL6
42 meningoencephalitis 10.3 TNF IL6 BDNF
43 dry eye syndrome 10.3 TNF IL6 BDNF
44 major affective disorder 8 10.3
45 major affective disorder 9 10.3
46 cyclic vomiting syndrome 10.3 IL6 CNR1
47 apnea, obstructive sleep 10.3 TNF IL6 HTR2A
48 prostatitis 10.3 TNF PRL IL6
49 posterior urethral valves 10.3 TNF IL6
50 neurofibromatosis, type ii 10.3 TNF PRL IL6

Comorbidity relations with Paranoid Schizophrenia via Phenotypic Disease Network (PDN): (show all 13)


Acute Cystitis Alzheimer Disease
Deficiency Anemia Delusional Disorder
Hypertension, Essential Hypothyroidism
Major Depressive Disorder Paranoid Personality Disorder
Parkinson Disease, Late-Onset Protein-Energy Malnutrition
Schizophrenia Schizophreniform Disorder
Tardive Dyskinesia

Graphical network of the top 20 diseases related to Paranoid Schizophrenia:



Diseases related to Paranoid Schizophrenia

Symptoms & Phenotypes for Paranoid Schizophrenia

MGI Mouse Phenotypes related to Paranoid Schizophrenia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.16 BDNF CNR1 COMT DISC1 DRD5 HTR1A
2 endocrine/exocrine gland MP:0005379 9.85 BDNF COMT DRD5 HTR2A IL6 NRXN1
3 homeostasis/metabolism MP:0005376 9.8 BDNF CNR1 COMT DISC1 HTR1A IL6
4 nervous system MP:0003631 9.47 BDNF CNR1 COMT DISC1 DRD5 HTR1A

Drugs & Therapeutics for Paranoid Schizophrenia

Drugs for Paranoid Schizophrenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 48)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cycloserine Approved Phase 4 68-41-7 401 6234
2
Ziprasidone Approved Phase 4 146939-27-7 60854
3
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
4 Serotonin Agents Phase 4
5 Dopamine Antagonists Phase 4
6 Serotonin Antagonists Phase 4
7 Anti-Infective Agents Phase 4
8 Renal Agents Phase 4
9 Antibiotics, Antitubercular Phase 4
10 Antitubercular Agents Phase 4
11 Anti-Bacterial Agents Phase 4
12 Anti-Infective Agents, Urinary Phase 4
13 Antimetabolites Phase 4
14 S 20098 Phase 4
15 Hypnotics and Sedatives Phase 4
16 Antidepressive Agents Phase 4
17 Central Nervous System Depressants Phase 4
18 Tranquilizing Agents Phase 4
19 Psychotropic Drugs Phase 4
20
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
21
Asenapine Approved Phase 3 85650-56-2, 65576-45-6 3001386
22
Risperidone Approved, Investigational Phase 2 106266-06-2 5073
23
Olanzapine Approved, Investigational Phase 2 132539-06-1 4585
24
Amisulpride Approved, Investigational Phase 2 71675-85-9, 53583-79-2 2159
25
Aripiprazole Approved, Investigational Phase 2 129722-12-9 60795
26 Quetiapine Fumarate Phase 2 111974-72-2
27 Epidiolex Phase 2
28 Anticonvulsants Phase 2
29
Oxytocin Approved, Vet_approved 50-56-6 439302 53477758
30
Dopamine Approved 51-61-6, 62-31-7 681
31
Raclopride Investigational 84225-95-6
32 Oxytocics
33 Serotonin Uptake Inhibitors
34 Sympathomimetics
35 Antiemetics
36 Gastrointestinal Agents
37 Protective Agents
38 Neurotransmitter Agents
39 Dopamine Agents
40 Antipsychotic Agents
41 Antiparkinson Agents
42
Benztropine 86-13-5 6832
43 Muscarinic Antagonists
44 Dopamine Uptake Inhibitors
45 Cholinergic Antagonists
46 Cholinergic Agents
47 Autonomic Agents
48 Parasympatholytics

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 Pilot Study of Pretreatment D-cycloserine for CBT-assessment of Paranoid Delusions in Schizophrenia Completed NCT00742079 Phase 4 D-cycloserine
2 Agomelatine Treatment of Major Depressive Episodes in the Course of Schizophrenic Psychoses (AGOPSYCH) Completed NCT01822418 Phase 4 agomelatine
3 D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions Completed NCT01981759 Phase 4 D-Cycloserine
4 An Open, Multicenter, Non-Comparative Study To Assess The Efficacy And Tolerability Of Intramuscular Ziprasidone Followed By Oral Ziprasidone In Patients With Acute Psychosis Completed NCT00644800 Phase 4 Ziprasidone
5 A Double-blind Randomized Placebo-controlled Trial of Adjuvant Therapy With Minocycline for Schizophrenia Completed NCT01809158 Phase 4 minocycline;placebo
6 Research Into Antipsychotic Discontinuation and Reduction (RADAR): A Randomised Controlled Trial Recruiting NCT03559426 Phase 4 Antipsychotic Reduction;Antipsychotic Maintenance
7 Phase 3 Randomized Controlled Trial of Cognitive Behavioural Therapy for Patients With Schizophrenia Unknown status NCT00300651 Phase 3
8 A 26-week, Multi-center, Open-label, Flexible Dose, Long-term Safety Trial of Asenapine in Adolescent Subjects With Schizophrenia Completed NCT01190267 Phase 3 asenapine
9 An 8-week, Placebo-controlled, Double-blind, Randomized, Fixed-dose Efficacy and Safety Trial of Asenapine in Adolescent Subjects With Schizophrenia Completed NCT01190254 Phase 3 asenapine 2.5 mg;asenapine 5.0 mg;placebo
10 Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset Psychosis Unknown status NCT00465920 Phase 2
11 Comparison of Emotion-focused Cognitive Behavior Therapy for Patients With Schizophrenia With Standard Treatment: Effects on Psychological Parameters and Rehospitalisation Unknown status NCT02787122 Phase 2
12 A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia Completed NCT00506077 Phase 2 MK0249;Comparator: Placebo (unspecified)
13 A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia Completed NCT00482430 Phase 2 MK0557;Comparator: Placebo (unspecified)
14 Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia: a Randomized, Controlled, Double Blind, Two-armed Clinical Trial Completed NCT01176721 Phase 2
15 A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects With Schizophrenia Completed NCT00103727 Phase 2 Talnetant
16 The Street Smart Group: A Feasibility Trial of a Group Intervention Targeting Anxiety Processes in Paranoia Completed NCT02408198 Phase 2
17 Enhancing Recovery in Early Schizophrenia - a Multi-center, Two-arm, Double-blind, Randomized Phase II Trial Investigating Cannabidiol vs. Placebo as an add-on to an Individualized Antipsychotic Treatment Recruiting NCT02926859 Phase 2 Cannabidiol as add-on;Placebo as add-on
18 Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone Unknown status NCT00563017 Long-acting Risperidone microspheres injection
19 Integrated Care in Patients With a Psychotic Disorder Fulfilling Definition of Severe Mental Illness (ACCESS-II Study) Unknown status NCT01888627
20 Psychoeducation in Patients With Schizophrenia: Neuropsychological Performance and Cognitive Training as Determinants of Outcome Unknown status NCT00646256
21 Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus Completed NCT00222807
22 Recovery After an Initial Schizophrenia Episode (RAISE): The RAISE Connection Program Duration of Untreated Psychosis (DUP) Completed NCT01216891
23 Acceptance and Commitment Therapy for Delusions Completed NCT00657631
24 Oxytocin Treatment of Social Deficits and Paranoia in Schizophrenia Completed NCT01028677 intranasal spray with oxytocin
25 The Minimal Effective Dose of Antipsychotic Medication in Older Patients With Schizophrenia: a PET Study. Completed NCT00716755 Risperidone/Olanzapine and PET scans
26 The Momentum Trial: The Efficacy of Using a Smartphone Application to Support Shared Decision Making Through Patient Activation in People With a Diagnosis of Schizophrenia in Outpatient Treatment Settings Recruiting NCT03554655
27 Individual Placement and Support (IPS) Enhanced With Cognitive Remediation and Social Skills Training in Denmark: a Randomized Controlled Trial Active, not recruiting NCT01722344
28 Quantitative Investigation of the Association Between the Social and Physical Features of the Environment and Participation for Those With Complex Mental Health Difficulties Living in Supported Accommodation Not yet recruiting NCT04106960
29 Evaluation of Treatment Outcomes in Schizophrenic Patients Taking Part in the Integrated Care Program - a Single-country, Multi-centre Non-interventional Study Terminated NCT00617214
30 Anticholinergic Burden in Schizophrenia Terminated NCT00715377 Benztropine

Search NIH Clinical Center for Paranoid Schizophrenia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Chlorprothixene

Cochrane evidence based reviews: schizophrenia, paranoid

Genetic Tests for Paranoid Schizophrenia

Anatomical Context for Paranoid Schizophrenia

MalaCards organs/tissues related to Paranoid Schizophrenia:

40
Brain, Testes, Eye, Thyroid, Cortex, Heart, Liver

Publications for Paranoid Schizophrenia

Articles related to Paranoid Schizophrenia:

(show top 50) (show all 1322)
# Title Authors PMID Year
1
Evidence of epistasis between the catechol-O-methyltransferase and aldehyde dehydrogenase 3B1 genes in paranoid schizophrenia. 54 61
19159868 2009
2
Demographic and clinical features as predictors of clozapine response in patients with schizophrenia spectrum disorders: A systematic review and meta-analysis. 61
31982601 2020
3
Assessment of cardiovascular disease risk factors in patients treated for schizophrenia. 61
32017819 2019
4
[The phenomenology of delusions of poisoning in persons with paranoid schizophrenia]. 61
31390658 2019
5
Brain-heart interactions considering complex physiological data: processing schemes for time-variant, frequency-dependent, topographical and statistical examination of directed interactions by convergent cross mapping. 61
31639776 2019
6
Simultaneous bilateral ulnar neuropathy: an unusual complication caused by neuroleptic treatment-induced tardive dyskinesia: A Case Report. 61
31702651 2019
7
Subacute combined degeneration of the spinal cord masking motor neuron disease: a case report. 61
31735167 2019
8
Association of HSPA1B Polymorphisms with Paranoid Schizophrenia in a Polish Population. 61
31642026 2019
9
Risk Factors for Noncompliance with Antipsychotic Medication in Long-Term Treated Chronic Schizophrenia Patients. 61
31488788 2019
10
Hypercalcaemia in a patient with paranoid schizophrenia - a case report. 61
31557139 2019
11
Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia. 61
31317083 2019
12
A coin crisis: a case report of pica with minireview. 61
31273687 2019
13
Fred J. Frese III (1940-2018). 61
31305107 2019
14
Polish version of the Brief Negative Symptom Scale (BNSS). 61
31522195 2019
15
Polish version of the Self-evaluation of Negative Symptoms (SNS). 61
31522196 2019
16
Paranoid schizophrenia and methamphetamine-induced paranoia are both characterized by a similar LINE-1 partial methylation profile, which is more pronounced in paranoid schizophrenia. 61
30826260 2019
17
Facial Emotion Recognition and Persecutory Ideation in Paranoid Schizophrenia. 61
31092137 2019
18
The Genealogy of Dementia Praecox I: Signs and Symptoms of Delusional Psychoses From 1880 to 1900. 61
29165678 2019
19
Postinjection Delirium/Sedation Syndrome After 31st Long-Acting Olanzapine Depot Injection. 61
30747749 2019
20
A telemedicine platform to improve clinical parameters in paranoid schizophrenia patients: Results of a one-year randomized study. 61
30154027 2019
21
Psychoeducational therapy with families of paranoid schizophrenia patients. 61
30745183 2019
22
The expression of toll-like receptors in peripheral blood mononuclear cells is altered in schizophrenia. 61
30616121 2019
23
Antisocial Personality Traits as a Risk Factor of Violence between Individuals with Mental Disorders. 61
30894931 2019
24
[Electroconvulsive therapy in treatment of resistant schizophrenia: biological markers of efficacy and safety]. 61
31089103 2019
25
Long non-coding RNA MIAT competitively binds miR-150-5p to regulate ZEB1 expression in osteosarcoma. 61
30655889 2019
26
Parkinsonism and Belly Dancer Syndrome in a Patient with Schizophrenia. 61
31498333 2019
27
[Does alcohol influence the cognitive functions of schizophrenic patients?] 61
31464284 2019
28
Narcissistic Equilibrium in Paranoid Schizophrenia. 61
31913789 2019
29
[The use of videooculography in schizophrenia]. 61
31089093 2019
30
Leukocytoclastic vasculitis secondary to clozapine. 61
30745661 2019
31
[The efficacy of remaxol as a hepatoprotective agent in long-term psychopharmacotherapy]. 61
31156221 2019
32
Elevated brain-derived neurotrophic factor (BDNF) serum levels in an acute episode of schizophrenia in polish women: Correlation with clinical and metabolic parameters. 61
30472511 2019
33
Maternal Infanticide and Filicide in a Psychiatric Custodial Institution in Hong Kong. 61
30563951 2018
34
Adherence, insight and disability in paranoid schizophrenia. 61
30278408 2018
35
Improvement in renal prognosis with prompt hemodialysis in hyperosmolar hyperglycemic state-related rhabdomyolysis: A case report. 61
30558060 2018
36
Unusual high blood glucose in ketoacidosis as first presentation of type 1 diabetes mellitus 61
30306778 2018
37
Potentially fatal outcomes associated with clozapine. 61
29503232 2018
38
Premorbid Adjustment in Predicting Symptom Severity and Social Cognitive Deficits in Schizophrenia. 61
30146494 2018
39
In schizophrenia serum level of neurotrophin-3 (NT-3) is increased only if depressive symptoms are present. 61
30098383 2018
40
Psychosocial roots of paranoid ideation: The role of childhood experiences, social comparison, submission, and shame. 61
29744971 2018
41
Comparative study of aggression - Dangerousness on patients with paranoid schizophrenia: Focus on demographic data, PANSS, drug use and aggressiveness. 61
30217324 2018
42
On the issue of choosing psychodiagnostic methods of measuring and scoring of cognitive deficit in case of schizophrenia. 61
29464816 2018
43
Towards a new classification of stable phase schizophrenia into major and simple neuro-cognitive psychosis: Results of unsupervised machine learning analysis. 61
29790237 2018
44
Chronotropic incompetence of the heart is associated with exercise intolerance in patients with schizophrenia. 61
29526454 2018
45
A within-subject consideration of the psychotic spectrum disorder concept in a patient in remission associated with cortical gray matter recovery. 61
29898284 2018
46
Therapeutic Particularities with Depot Medications in Schizophrenia. 61
30647956 2018
47
Association Studies of HSPA1A and HSPA1L Gene Polymorphisms With Schizophrenia. 61
30342847 2018
48
Human cathelicidin LL-37 - Does it influence the homeostatic imbalance in mental disorders? 61
29872020 2018
49
Brain and Behavior: Commentary on Two Cases Involving the Effect of Structural Brain Lesions on Psychiatric Disorders. 61
30015791 2018
50
Zotepine-induced convulsion at a low dose in a case of paranoid schizophrenia. 61
29363876 2018

Variations for Paranoid Schizophrenia

Expression for Paranoid Schizophrenia

Search GEO for disease gene expression data for Paranoid Schizophrenia.

Pathways for Paranoid Schizophrenia

Pathways related to Paranoid Schizophrenia according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1 12.38 TPH2 S100B NTRK2 HTR1A COMT CNR1
2 11.72 TPH2 SLC6A4 MAOA HTR2A HTR1A
3
Show member pathways
11.55 MAOA COMT ALDH3B1
4 11.5 TNF IL6 BDNF
5 11.49 TPH2 TNF SLC6A4 NTRK2 MAOA IL6
6 11.36 TNF IL6 HSPA1L
7
Show member pathways
11.26 TPH2 TNF SLC6A4 MAOA
8
Show member pathways
11 SLC6A4 MAOA COMT
9 11 TPH2 SLC6A4 MAOA HTR2A HTR1A
10
Show member pathways
10.79 TPH2 SLC6A4 MAOA HTR1A DRD5 COMT
11
Show member pathways
10.62 MAOA ALDH3B1
12 10.41 TNF PRL

GO Terms for Paranoid Schizophrenia

Cellular components related to Paranoid Schizophrenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.76 TNF SLC6A4 NTRK2 NRXN1 HTR2A HTR1A
2 synapse GO:0045202 9.73 SLC6A4 NTRK2 NRXN1 HTR1A DRD5 DISC1
3 dendrite GO:0030425 9.72 NTRK2 HTR2A HTR1A COMT BDNF
4 cell body GO:0044297 9.54 HSPA1L DISC1 COMT
5 axon GO:0030424 9.43 NTRK2 HTR2A DISC1 COMT CNR1 BDNF
6 integral component of presynaptic membrane GO:0099056 8.92 SLC6A4 NRXN1 HTR2A CNR1

Biological processes related to Paranoid Schizophrenia according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.96 TNF SLC6A4 NTRK2 NRXN1 IL6
2 chemical synaptic transmission GO:0007268 9.91 NRXN1 HTR2A HTR1A DRD5
3 positive regulation of cell proliferation GO:0008284 9.88 S100B PRL NTRK2 IL6 HTR2A HTR1A
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.85 TNF NTRK2 NRXN1 HTR2A
5 circadian rhythm GO:0007623 9.8 TPH2 SLC6A4 NTRK2
6 positive regulation of neuron projection development GO:0010976 9.73 NTRK2 DISC1 CNR1 BDNF
7 learning GO:0007612 9.71 NTRK2 NRXN1 COMT
8 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.7 HTR2A HTR1A CNR1
9 positive regulation of synapse assembly GO:0051965 9.69 NTRK2 NRXN1 BDNF
10 positive regulation of neuroinflammatory response GO:0150078 9.62 TNF IL6
11 behavior GO:0007610 9.61 HTR2A HTR1A
12 neurotransmitter catabolic process GO:0042135 9.6 MAOA COMT
13 catecholamine metabolic process GO:0006584 9.59 MAOA COMT
14 dopamine catabolic process GO:0042420 9.58 MAOA COMT
15 negative regulation of lipid storage GO:0010888 9.58 TNF IL6
16 serotonin receptor signaling pathway GO:0007210 9.57 HTR2A HTR1A
17 regulation of synaptic transmission, glutamatergic GO:0051966 9.54 TNF DISC1 CNR1
18 activation of phospholipase C activity GO:0007202 9.5 NTRK2 HTR2A BDNF
19 positive regulation of non-membrane spanning protein tyrosine kinase activity GO:1903997 9.49 NTRK2 BDNF
20 positive regulation of fever generation GO:0031622 9.48 TNF CNR1
21 brain-derived neurotrophic factor receptor signaling pathway GO:0031547 9.46 NTRK2 BDNF
22 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.46 TNF NTRK2 NRXN1 IL6
23 positive regulation of JAK-STAT cascade GO:0046427 9.43 TNF PRL IL6
24 response to glucocorticoid GO:0051384 9.26 TPH2 TNF S100B IL6
25 memory GO:0007613 9.02 SLC6A4 S100B HTR2A CNR1 BDNF

Molecular functions related to Paranoid Schizophrenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serotonin binding GO:0051378 8.8 SLC6A4 HTR2A HTR1A

Sources for Paranoid Schizophrenia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....